Prescriber Scope of Practice for ADHD in Georgia

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD treatment, you’ve probably asked yourself: Can I legally prescribe Adderall or other stimulants through a video visit? The answer is yes—through at least December 31, 2026—but with important caveats that vary by state and provider type.

Let’s cut through the confusion. The federal rules that govern controlled substance prescribing have been in flux since COVID, state laws differ wildly, and if you’re an NP, your scope of practice might look completely different in Texas than it does in California. This matters because getting it wrong means serious regulatory risk, and getting it right means you can help thousands of underserved ADHD patients while building a sustainable telehealth practice.

Here’s what you actually need to know to prescribe ADHD medications via telehealth in 2026—backed by current federal regulations and state-specific rules for California, Texas, Florida, New York, Pennsylvania, and Illinois.

The Federal Landscape: DEA Rules Through 2026

Current Status: Telehealth Prescribing Is Legal (For Now)

The Ryan Haight Act normally requires an in-person exam before prescribing any controlled substance. That’s federal law. But COVID changed everything.

The DEA and HHS have extended telehealth flexibilities through December 31, 2026, allowing providers to prescribe Schedule II–V controlled substances—including Adderall, Vyvanse, and other ADHD medications—without an initial in-person visit. This is the fourth extension of the emergency COVID-era waiver.

What this means practically: You can evaluate a new ADHD patient via video telehealth and prescribe stimulants on the same day, as long as you:

• Use real-time audio-video communication (not just phone or questionnaire)
• Conduct a legitimate medical evaluation meeting the standard of care
• Issue the prescription for a legitimate medical purpose
• Use electronic prescribing (EPCS) as required
• Check your state’s Prescription Drug Monitoring Program (PDMP)
• Are licensed in the patient’s state with appropriate DEA registration

This flexibility has enabled thousands of providers to deliver ADHD care remotely. But it’s temporary.

What Happens After 2026?

The DEA is working on permanent telemedicine rules. In January 2025, they previewed three new regulations that will likely take effect in 2027:

1. Telemedicine Special Registration: Providers will be able to obtain a special DEA registration authorizing controlled substance prescribing via telehealth without in-person exams. This will include new safeguards:

• Mandatory nationwide PDMP checks
• Strict patient identity verification during video consults
• Oversight of telehealth platforms themselves (companies must register with DEA)

2. Established Patient Exception: If you’ve seen a patient in person at least once (or another provider in your practice has), the telemedicine rules won’t apply to ongoing care. But purely online practices will need the special registration.

3. Modified Initial Prescribing Rules: The DEA initially proposed limiting telehealth providers to a 30-day supply without an in-person visit, but that rule was shelved after massive pushback. The final version will likely be less restrictive while still including patient protections.

Bottom line: Telehealth ADHD prescribing isn’t going away, but providers should prepare to obtain the special DEA registration and comply with enhanced PDMP requirements when the new rules drop in 2027.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where It Gets Complicated

Federal law sets the floor, but states can add their own requirements—and they vary dramatically. Here’s what you need to know for our six priority states.

California: Provider-Friendly with Growing NP Independence

Telehealth prescribing: California has no state-level ban on prescribing controlled substances via telehealth. State law explicitly allows telehealth encounters to satisfy the ‘appropriate prior examination’ requirement for prescribing. You don’t need an in-person visit by California law—just a clinically appropriate telehealth evaluation.

What you must do:

• Check the CURES PDMP before the initial prescription and at least every 4 months for ongoing stimulant therapy (mandatory by state law)
• Use a video visit for the evaluation (meets standard of care)
• Document informed consent for telehealth

NP scope of practice: California is transitioning to Full Practice Authority for nurse practitioners. Under AB 890 (passed in 2020), experienced NPs can practice independently after completing either:

• 3 years of physician-supervised practice, OR
• 4,600 hours of supervised practice

By 2026, qualifying PMHNPs can prescribe ADHD medications without physician oversight. New graduate NPs still need a supervising physician until they meet the requirements.

Licensure: You must hold a California medical or nursing license. California is not part of the Interstate Medical Licensure Compact (IMLC), so out-of-state physicians need a full California license (which takes time). No shortcuts.

Key takeaway: California is becoming one of the most PMHNP-friendly states for telehealth ADHD care, but the licensing process for out-of-state providers is a barrier.

Texas: Physicians Only for Stimulants

Telehealth prescribing: Texas allows telemedicine and doesn’t ban controlled substance prescribing for mental health via telehealth. Psychiatrists can prescribe stimulants through video visits following federal rules.

The NP problem: Texas has one of the most restrictive NP scopes in the country. Nurse practitioners and physician assistants cannot prescribe Schedule II controlled substances in outpatient settings. Period.

The only exceptions are:

• Hospital inpatient orders (≥24-hour admission)
• Hospice patients
• Emergency department medication orders

Outpatient ADHD treatment doesn’t qualify. This means only physicians (MD/DO) can prescribe Adderall, Ritalin, or other stimulants for telehealth ADHD patients in Texas.

If you’re a PMHNP practicing on a telehealth platform in Texas, you can evaluate the patient, but a physician must write the prescription.

PDMP requirements: Texas law mandates PDMP checks for opioids, benzodiazepines, barbiturates, and carisoprodol—but not technically for stimulants. Still, checking the Texas PMP for any controlled substance history is best practice and expected by most auditors.

E-prescribing: Mandatory for all controlled substances in Texas (as of 2021). You need EPCS technology.

Key takeaway: If you’re building a telehealth ADHD practice in Texas, budget for physician involvement. NPs can handle everything except signing the prescription.

Florida: Explicit Psychiatric Exception

Telehealth prescribing: Florida law is unusually clear. Under Florida Statutes §456.47, providers cannot prescribe Schedule II controlled substances via telehealth except for:

1. Treatment of a psychiatric disorder (ADHD qualifies)
2. Inpatient hospital treatment
3. Hospice care
4. Nursing home residents

Since ADHD is a psychiatric disorder, you can legally prescribe stimulants via telehealth in Florida without an in-person visit. This exception was intentionally included when Florida updated its telehealth laws in 2019.

Out-of-state provider option: Florida has a unique telehealth registration for out-of-state providers. If you’re licensed in another state, you can register with the Florida Department of Health to provide telehealth services to Florida patients—including prescribing ADHD medications under the psychiatric exception—without getting a full Florida license.

Requirements:

• Active, unrestricted license in another state
• Clean disciplinary record for 5 years
• Malpractice insurance
• Register with Florida’s PDMP (E-FORCSE)

PDMP: You must check E-FORCSE before prescribing controlled substances to patients age 16 or older (with limited exceptions for 3-day supplies).

NP scope: Florida allows PMHNPs to prescribe ADHD medications, but they must work under a protocol agreement with a supervising psychiatrist. The good news: ‘psychiatric nurses’ (PMHNPs with advanced psych training and 2+ years of post-grad clinical experience) are exempt from the 7-day limit on Schedule II prescriptions that applies to other NPs. They can write full-length stimulant prescriptions.

For other APRNs in Florida, Schedule II prescriptions are limited to 7 days for acute conditions.

Key takeaway: Florida’s explicit psychiatric exception and out-of-state registration option make it accessible for telehealth ADHD providers, but NPs need physician collaboration.

New York: Recently Aligned with Federal Law

Telehealth prescribing: In May 2025, New York updated its regulations to explicitly allow prescribing controlled substances via telehealth when consistent with federal law. This aligned state rules with the DEA’s extended flexibilities.

Translation: As long as the federal extension is in effect (through 2026), you can prescribe ADHD medications via telehealth in New York without an in-person exam.

What you must do:

• Check the I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance (mandatory)
• Use electronic prescribing (required for all controlled substances since 2016)
• Conduct evaluation via live two-way video

NP scope: New York is fairly progressive. Under the NP Modernization Act (2015), experienced NPs with more than 3,600 hours of practice can practice independently without a written collaborative agreement. They must still have a defined collaborative relationship with a physician, but no direct supervision is required.

PMHNPs in New York can prescribe Schedule II–V controlled substances with their own DEA registration and no quantity limits beyond what physicians face.

Unique advantage: New York allows stimulant prescriptions for ADHD in up to a 90-day supply if you indicate the prescription is for ‘minimal brain dysfunction’ (the old term for ADHD) or narcolepsy by assigning Code B on the prescription. This works for both physicians and NPs and reduces prescription hassle for stable patients.

Licensure: You must hold a New York medical or nursing license. NY is not part of IMLC, so out-of-state physicians need a full license.

Key takeaway: New York’s 2025 regulatory update removed state-level barriers, and the 90-day supply option makes ongoing ADHD care more efficient via telehealth.

Pennsylvania: Collaborative Model with 30-Day NP Limit

Telehealth prescribing: Pennsylvania has no state law prohibiting controlled substance prescribing via telehealth. The state medical boards permit telemedicine prescribing if the encounter meets the standard of care—which video visits can satisfy.

PA defers to federal law on the in-person exam requirement, so during the DEA extension period, you can prescribe ADHD medications via telehealth.

E-prescribing: Mandatory for controlled substances (with few exceptions) since October 2019.

PDMP: Pennsylvania law requires checking the PA PDMP before prescribing any controlled substance at the start of a new course of treatment, and each time for opioids and benzodiazepines. While not explicitly required for every stimulant refill, best practice is to check the PDMP for each ADHD prescription.

NP scope: Pennsylvania is a restricted practice state. Certified Registered Nurse Practitioners (CRNPs) must have a collaborative agreement with a physician to practice and prescribe.

For controlled substances:

• Schedule II: NPs can prescribe up to a 30-day supply
• Any continuation beyond 30 days requires physician approval
• Schedule III/IV: Up to 90-day supply allowed

For ADHD stimulants (Schedule II), this means your PMHNP can write the initial one-month prescription, but for month #2 and beyond, the collaborating psychiatrist needs to review and approve ongoing treatment. The physician doesn’t have to see the patient or co-sign every prescription, but they must be involved in care decisions.

Licensure: Pennsylvania is part of the Interstate Medical Licensure Compact, so out-of-state physicians can expedite licensure. NPs need a full PA license.

Key takeaway: The 30-day NP limit on Schedule II prescriptions means you need physician involvement for ongoing ADHD care if you’re using PMHNPs in Pennsylvania.

Illinois: Two-Tier NP System

Telehealth prescribing: Illinois allows telehealth broadly and has no state-imposed barriers to prescribing controlled substances via telemedicine beyond federal requirements. The state updated its Telehealth Act in 2021 to ensure parity and explicitly allow provider-patient relationships to be established via telehealth.

Controlled substance licensing: Any provider who prescribes controlled substances in Illinois must obtain an Illinois Controlled Substance License in addition to their DEA registration. This is an extra administrative step for out-of-state providers.

PDMP: Illinois law requires documenting a PMP check for each opioid prescription and initial benzodiazepine prescription. While not explicitly mandatory for stimulants, checking the Illinois PMP (AWARxE) for any controlled substance is recommended and expected.

NP scope – Two pathways:

1. Full Practice Authority (FPA): Illinois APRNs who have completed 4,000 hours of clinical practice under physician collaboration and 250 hours of continuing education can apply for FPA licensure. FPA APRNs can prescribe Schedule II–V controlled substances independently with two exceptions:

• For Schedule II narcotic drugs (opioids) or benzodiazepines, they must have a consultation relationship with a physician
• This consultation requirement does NOT apply to stimulants (which are Schedule II non-narcotic substances)

Translation: An Illinois PMHNP with FPA can prescribe Adderall completely independently via telehealth—no physician oversight needed.

2. Collaborative Agreement: NPs without FPA must work under a written collaborative agreement with a physician. For controlled substances:

• Schedule II prescriptions limited to 30-day supply
• Any continuation beyond 30 days requires physician approval
• Physician must review the NP’s Schedule II prescribing monthly

Unique wrinkle: Illinois is one of few states that allows prescribing psychologists (clinical psychologists with advanced training) to prescribe psychotropic medications under physician collaboration. However, they are prohibited from prescribing Schedule II substances, so ADHD medication management still falls to MDs, DOs, NPs, and PAs.

Licensure: Illinois is part of IMLC for physicians. APRNs need an Illinois license plus the state controlled substance license.

Key takeaway: Illinois’s FPA pathway makes it one of the best states for independent PMHNP practice in telehealth ADHD care—if the NP has met the experience and training requirements.

State Comparison Table: Quick Reference

The Economics of Telehealth ADHD Practice

Here’s what nobody talks about: patient acquisition cost.

If you’re thinking about building your own telehealth ADHD practice through DIY marketing, understand the real numbers:

Traditional marketing channels:

• SEO: Takes 6–12 months of consistent investment before generating meaningful patient flow. You need content creation, link building, technical optimization—most solo providers don’t have the expertise or patience.
• Google Ads: Mental health keywords cost $15–40+ per click. Most clicks don’t convert. Realistic cost per booked patient through PPC is $200–400+ after you factor in ad spend, testing, optimization, and no-show rates.
• Directory listings (Psychology Today, Zocdoc): Monthly subscription fees plus you compete with hundreds of other providers on the same page. Zocdoc charges $35–100+ per booking, and that’s on top of the monthly platform fee.

When you add up agency/consultant fees, ad spend, staff time to handle and qualify leads, no-show rates from cold leads, and months of testing failed campaigns, acquiring a qualified psychiatric patient through DIY marketing typically costs $200–500+—if you can make it work at all.

Most providers starting out or scaling up don’t have $3,000–5,000/month to gamble on marketing with uncertain results.

Platform model (Klarity Health): Instead of upfront marketing spend and monthly subscriptions, you pay a standard listing fee per new patient lead on a pay-per-appointment basis. The value proposition:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

Guaranteed ROI vs gambling on marketing channels. For most providers, especially those starting out or scaling, a platform that handles patient acquisition removes the risk entirely.

DIY marketing can eventually be cost-effective if you have the budget, expertise, and patience to build an SEO presence over 12+ months—but for most providers, that’s not realistic when you’re trying to fill your schedule this quarter.

What This Means for Your Practice

If you’re a psychiatrist:

• You have full prescribing authority in every state (with proper licensure and DEA registration)
• Telehealth ADHD prescribing is legal federally through 2026, and most states don’t add barriers
• Main considerations: multi-state licensing strategy, PDMP compliance, e-prescribing setup
• Watch for DEA’s permanent rules in 2027 and plan to obtain the special telemedicine registration

If you’re a PMHNP:

• Your scope varies dramatically by state
• Best states for independent practice: California (by 2026), Illinois (with FPA), New York (after 3,600 hours)
• Collaborative states: Florida, Pennsylvania, Illinois (without FPA)—you’ll need physician involvement
• Restrictive state: Texas—you can evaluate patients but cannot prescribe stimulants

What you should do now:

1. Verify your state’s current rules for your license type (scope of practice can change—check your state medical or nursing board website)
2. Get credentialed for e-prescribing controlled substances (EPCS) if you haven’t already
3. Register with PDMPs in every state where you’ll practice and build the habit of checking before prescribing
4. Document everything: Your telehealth evaluation must clearly meet the standard of care—detailed history, DSM-5 criteria for ADHD diagnosis, discussion of risks/benefits, treatment plan
5. Stay current on DEA rulemaking—subscribe to updates from DEA or industry groups so you’re not caught off guard when permanent rules drop

Joining a Telehealth Platform vs Going Solo

The regulatory complexity alone—tracking federal extensions, navigating six different state rule sets, managing PDMP registrations, setting up EPCS, handling multi-state licensing—is why many providers choose to join an established platform rather than build from scratch.

What platforms like Klarity Health handle:

• Patient acquisition and matching (no marketing budget needed)
• Compliance infrastructure (PDMP integration, e-prescribing technology)
• Telehealth platform and EHR
• Credentialing support across multiple states
• Ongoing regulatory updates (you get notified when rules change)

What you keep:

• Clinical autonomy—you decide diagnosis and treatment
• Schedule control—you set your availability
• Revenue on every patient you see (pay-per-appointment, not revenue share that cuts into your earnings)

For providers who want to focus on clinical care rather than becoming marketing experts and compliance specialists, platforms remove the barriers that keep most psychiatrists and PMHNPs from scaling telehealth ADHD practices.

Next Steps

Telehealth ADHD care is legal, growing, and needed—but only if you navigate the regulations correctly.

Whether you’re a psychiatrist looking to expand into telehealth or a PMHNP exploring your scope of practice in a new state, understanding these federal and state rules is non-negotiable. The risk of getting it wrong (DEA violations, medical board complaints, liability exposure) is too high, and the opportunity cost of sitting on the sidelines (while underserved ADHD patients wait months for care) is too great.

If you’re ready to start treating ADHD patients via telehealth without the headache of building everything from scratch, explore joining Klarity Health’s provider network. We handle patient acquisition, compliance infrastructure, and telehealth technology—you handle the clinical care you were trained to provide.

Questions about your specific state or license type? Reach out to our provider relations team. We’ll walk you through scope of practice requirements, licensing, and what it takes to get started in your state.

The federal extension runs through 2026. The demand for ADHD care isn’t going anywhere. The question is whether you’ll be positioned to meet it.

Frequently Asked Questions

Can I prescribe ADHD medications on the first telehealth visit?

Yes, under current federal rules (extended through December 31, 2026), you can evaluate a new patient via live video and prescribe stimulants on the same day, provided you conduct a thorough evaluation meeting the standard of care, check the PDMP, and comply with state-specific requirements. This applies in all states except Texas (where NPs cannot prescribe Schedule II at all in outpatient settings).

Do I need to see ADHD patients in person eventually?

Not under current federal or most state laws. As long as the DEA extension is in effect, there’s no mandatory in-person follow-up for telehealth ADHD care. Pending DEA permanent rules (expected 2027) may create a pathway for ongoing telehealth-only treatment via special registration, but details aren’t final yet. Clinically, you should see patients in person if their condition requires it, but regulations don’t mandate it for stable telehealth patients currently.

Can psychiatric nurse practitioners prescribe Adderall in all 50 states?

No. While PMHNPs can treat ADHD patients in all 50 states, prescriptive authority for Schedule II stimulants varies:

• Cannot prescribe Schedule II outpatient: Texas (physician must prescribe)
• Can prescribe with collaboration/supervision: Florida, Pennsylvania, Illinois (without FPA)
• Can prescribe independently (if criteria met): California (by 2026 with experience), Illinois (with FPA), New York (after 3,600 hours), and several other states with full practice authority

Always verify your state’s current scope of practice rules.

What happens if the DEA doesn’t extend the telehealth waiver past 2026?

The DEA has committed to finalizing permanent telemedicine rules before the current extension expires December 31, 2026. Based on their January 2025 announcements, those rules will create a ‘Telemedicine Special Registration’ allowing providers to continue prescribing controlled substances via telehealth with added safeguards (PDMP checks, patient ID verification). The goal is to preserve telehealth access while preventing abuse—not to eliminate tele-prescribing for legitimate ADHD care.

Do I need separate DEA registrations for each state where I practice telehealth?

Yes. You need a DEA registration for each state where your patients are located at the time of treatment. So if you’re treating patients in California, New York, and Florida via telehealth, you need three separate state DEA registrations (each tied to a physical address in that state—which can be your practice address, even if you’re providing care remotely). This is federal DEA policy.

Are there any controlled substance prescription limits I should know about?

It depends on your license type and state:

• Federal: No specific quantity limits during the current extension, but the prescription must be for a legitimate medical purpose
• NP limits: Pennsylvania and Illinois (without FPA) restrict NPs to 30-day supplies of Schedule II; Florida limits non-psychiatric NPs to 7 days
• Physicians: Generally no state-imposed quantity limits beyond what’s medically appropriate, though some states have reporting requirements for high-dose or long-term prescriptions

New York uniquely allows up to 90-day supplies for ADHD if properly documented.

What are the penalties for non-compliance with telehealth prescribing rules?

Violations of the Controlled Substances Act (including the Ryan Haight Act) can result in:

• DEA registration suspension or revocation
• Civil monetary penalties ($10,000+ per violation)
• Criminal prosecution (in egregious cases)
• State medical/nursing board discipline (license suspension, practice restrictions)

Even unintentional violations (like failing to check PDMP when required, or prescribing outside your scope of practice) can trigger investigations. This is why understanding both federal and state rules for your license type is critical.

Sources and References

The following sources were consulted to ensure accuracy and regulatory compliance. All information reflects laws and regulations current as of February 2026.

Federal Sources

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026)
   https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html
   Official government announcement confirming fourth extension of controlled substance telehealth prescribing through December 31, 2026

2. Healthcare Dive – DEA, HHS Extend Telehealth Controlled Substance Prescribing Flexibilities (January 5, 2026)
   https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/
   Industry news coverage of federal extension, clarifying scope of Schedule II-V substances

3. DEA Press Release – Three New Telemedicine Rules (January 16, 2025)
   https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access
   Official DEA summary of proposed permanent rules including special registration and PDMP requirements

4. RxAgent Blog – NP Prescriptive Authority by State (2026 Guide) (December 28, 2025)
   https://rxagent.co/blog/np-prescribing-authority
   Comprehensive state-by-state analysis of nurse practitioner scope of practice and prescribing authority

State-Specific Sources

5. Texas Board of Nursing – APRN Practice FAQ
   https://www.bon.texas.gov/faqpracticeaprn.asp.html
   Official Texas BON guidance confirming NP/PA restrictions on Schedule II prescribing in outpatient settings

6. Florida Statutes §456.47 – Telehealth
   http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html
   Primary legal text establishing psychiatric disorder exception for telehealth Schedule II prescribing

7. Florida Statutes §464.012 – Advanced Practice Registered Nurse Prescribing
   http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&StatuteYear=2017&URL=0400-0499/0464/Sections/0464.012.html
   Florida law on APRN prescribing authority, including 7-day limit and psychiatric nurse exception

8. New York State Department of Health – Guidance on Prescribing Controlled Substances via Telehealth (May 2025)
   https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth
   Official NYSDOH guidance aligning state regulations with federal telehealth allowances

9. Pennsylvania Code Title 49 Chapter 21 – CRNP Prescriptive Authority Regulations
   https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html
   Official Pennsylvania administrative code establishing 30-day limit on NP Schedule II prescriptions

10. Illinois Administrative Code Title 68 Part 1300 – Advanced Practice Nursing
    https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300
    Illinois regulations on APRN collaboration, full practice authority, and controlled substance prescribing limits

11. California Business & Professions Code §2242 (via CCHP State Telehealth Laws)
    https://www.cchpca.org/topic/online-prescribing/
    Center for Connected Health Policy compilation of state laws, citing California statute allowing telehealth exams for prescribing

All regulatory claims have been verified against official government sources (state statutes, medical/nursing board publications, and federal agency announcements). Information reflects laws current as of February 10, 2026.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care